Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
The AAPS Journal
|
March 19, 2020
Applying Beta Distribution in Analyzing Bounded Outcome Score Data
Chuanpu Hu, Honghui Zhou, Amarnath Sharma
Journal of Clinical Pharmacology
|
August 12, 2021
Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients
Yuki Iwaki, Sayori Shibata, Chuanpu Hu
Pharmaceutical Statistics
|
December 31, 2009
Confirmatory analysis for phase III population pharmacokinetics
Chuanpu Hu, Ji Zhang, Honghui Zhou
The AAPS Journal
|
July 24, 2020
Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents
Chuanpu Hu, Honghui Zhou, Amarnath Sharma
The AAPS Journal
|
July 23, 2020
Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data
Chuanpu Hu, Honghui Zhou, Amarnath Sharma
Journal of Pharmacokinetics and Pharmacodynamics
|
August 18, 2024
Visual predictive check of longitudinal models and dropout
Chuanpu Hu, Anna G Kondic, Amit Roy
Journal of Pharmacokinetics and Pharmacodynamics
|
May 24, 2014
Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis
Chuanpu Hu, Yasmine Wasfi, Yanli Zhuang, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
June 22, 2017
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients
Chuanpu Hu, Bruce Randazzo, Amarnath Sharma, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
January 17, 2023
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis
Chuanpu Hu, Marion Vetter, An Vermeulen, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
August 1, 2021
Pharmacokinetic Modeling and Predictive Performance: Practical Considerations for Therapeutic Monoclonal Antibodies
Yang Chen, Joshua Li, Derry Li, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
The AAPS Journal
|
March 19, 2020
Applying Beta Distribution in Analyzing Bounded Outcome Score Data
Chuanpu Hu, Honghui Zhou, Amarnath Sharma
Journal of Clinical Pharmacology
|
August 12, 2021
Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients
Yuki Iwaki, Sayori Shibata, Chuanpu Hu
Pharmaceutical Statistics
|
December 31, 2009
Confirmatory analysis for phase III population pharmacokinetics
Chuanpu Hu, Ji Zhang, Honghui Zhou
The AAPS Journal
|
July 24, 2020
Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents
Chuanpu Hu, Honghui Zhou, Amarnath Sharma
The AAPS Journal
|
July 23, 2020
Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data
Chuanpu Hu, Honghui Zhou, Amarnath Sharma
Journal of Pharmacokinetics and Pharmacodynamics
|
August 18, 2024
Visual predictive check of longitudinal models and dropout
Chuanpu Hu, Anna G Kondic, Amit Roy
Journal of Pharmacokinetics and Pharmacodynamics
|
May 24, 2014
Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis
Chuanpu Hu, Yasmine Wasfi, Yanli Zhuang, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
June 22, 2017
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients
Chuanpu Hu, Bruce Randazzo, Amarnath Sharma, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
January 17, 2023
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis
Chuanpu Hu, Marion Vetter, An Vermeulen, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
August 1, 2021
Pharmacokinetic Modeling and Predictive Performance: Practical Considerations for Therapeutic Monoclonal Antibodies
Yang Chen, Joshua Li, Derry Li, et al.
Page
of 6